TrumpRx GLP-1 prices: how the site works in 2026

TrumpRx.gov is a federal website that lists the lowest manufacturer self-pay prices and routes you to the maker’s channel. It is not insurance, and it does not replace your pharmacy benefit or your plan’s copay rules. Think of it as a directory for cash-pay options offered by manufacturers. Always confirm the current listing at the time you use the site, because prices and programs change often.

Listings may differ by brand and by form, such as pens, vials, or tablets. As of July 2026, examples that have appeared include Wegovy (all forms), Zepbound, and Foundayo, but the exact options you see can change. Also note device differences: Zepbound KwikPen (approved February 2026) is a multi-dose pen that holds a month of doses, and single-dose pens and vials also exist. Match the listing to the same product form your prescription is written for.

TrumpRx.gov typically routes you to the manufacturer’s program or fulfillment path, like LillyDirect for Eli Lilly medicines or NovoCare for Novo Nordisk medicines. For example, Foundayo (orforglipron) launched April 6, 2026 and is available via LillyDirect, telehealth, and retail pharmacies. Follow the routing links carefully so you land on the official enrollment, telehealth, or pharmacy pathway. If you are unsure, ask your pharmacist to confirm you are using the legitimate manufacturer route.

A “lowest self-pay price” is not always your best price if you have insurance, a manufacturer savings card, or Part D coverage. For Foundayo, Eli Lilly has offered self-pay starting at $149/month for the lowest dose and a commercial savings card as low as $25/month for eligible patients, at the time of writing. Your eligibility depends on your insurance type and program rules, so confirm directly with the manufacturer. If you have a high deductible plan, compare what you would pay through insurance versus the listed self-pay route before you decide how to fill.

Starting July 1, 2026, CMS began a temporary Medicare GLP-1 Bridge demonstration that runs through December 31, 2027. Eligible Part D enrollees pay a $50/month copay for covered GLP-1s (it does not count toward the deductible or out-of-pocket max) and it requires prior authorization. Covered medicines include Wegovy (all forms), Foundayo, and Zepbound KwikPen, with eligibility tied to age and BMI and certain conditions. If you think you qualify, ask your plan or prescriber’s office how to submit the prior authorization under the demonstration.

TrumpRx.gov lists manufacturer programs, so it may not help you price compounded GLP-1 versions. If you see “retatrutide” sold online, know that retatrutide is not FDA approved as of July 2026 and is not legally prescribable outside clinical trials. CagriSema has been submitted to the FDA (December 18, 2025) but is not approved as of this date. For any product you are considering, use your pharmacist as a checkpoint for legitimacy and safe sourcing.